ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Soft tissue sarcoma, adult
Stage/Subtype:  stage IV adult soft tissue sarcoma
Trial Type:  Treatment
Results 1-25 of 69 for your search:
Start Over
Radiation Therapy with or without Combination Chemotherapy or Pazopanib Hydrochloride before Surgery in Treating Patients with Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 and over
Trial IDs: ARST1321, NCI-2014-01340, NCT02180867
Selinexor in Advanced Liposarcoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 12 and over
Trial IDs: KCP-330-020, NCI-2016-00746, 2015-003594-14, NCT02606461
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 4 to 55
Trial IDs: ADP 04511, NCI-2015-00410, NCI-2013-01481, UPCC 04511, NCT01343043
Image-Guided Intensity-Modulated Proton or Photon Beam Radiation Therapy with Boost in Treating Patients with Primary or Locally Recurrent Soft Tissue Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-100, NCI-2012-01931, NCT01659203
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-104, NCI-2013-01735, UPCI 12-104, NCT01879085
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105SAR101, NCI-2014-00305, NCT01975519
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, 348360, P131392, NCT02054104
Talimogene Laherparepvec and Preoperative Radiation Therapy in Treating Patients with Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201504731, NCI-2015-01193, 20139075, NCT02453191
PLX3397 and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO6059, NCI-2015-01768, NCT02584647
Sapanisertib or Pazopanib Hydrochloride in Treating Patients with Locally Advanced or Metastatic Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091304, NCI-2015-01929, NCT02601209
Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 30
Trial IDs: GO29665, NCI-2016-00541, 2014-004685-25, NCT02639546
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: 15839, NCI-2016-00652, 2015-001316-34, I5B-MC-JGDL, NCT02659020
Plicamycin in Treating Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas, or Germ Cell Tumors with Pleuropulmonary Metastases
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0152, NCI-2016-01247, P152145, NCT02859415
Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients with Sarcoma That is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9624, NCI-2016-01286, NCT02888665
Proton Beam Radiation Therapy in Treating Younger Patients with Bone or Non-rhabdomyosarcoma Soft Tissue Sarcomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 30 and under
Trial IDs: 05-326, NCI-2012-00673, NCT00592293
Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 8463, NCI-2013-01452, 090192, P09512, 09-C-0192, NCT00942877
Gemcitabine Hydrochloride with or without Pazopanib Hydrochloride in Treating Patients with Refractory Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: 7943, NCI-2012-00052, NCT01532687
Gemcitabine Hydrochloride and Docetaxel or Pazopanib Hydrochloride in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 90
Trial IDs: 101644, NCI-2012-00675, CPZP034BUS1T, CPZP034BUS21T, MUSC 101644, PAZ115785, PZP115785, NCT01593748
Cabozantinib-S-Malate in Treating Patients with Refractory Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9284, NCI-2012-03124, 09-25-0099, 121088, 130044, P121088, P9284_A07PAMDREVW01, 13-C-0044, NCT01755195
Hypofractionated Stereotactic Radiation Therapy in Treating Younger Patients with Metastatic Sarcomas of Bony Sites
Status: Active
Phase: Phase II
Type: Treatment
Age: Greater than 3 to less than or equal to 40
Trial IDs: J1367, NCI-2013-02433, NA_00070109, NCT01763970
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NCT01804634
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Regorafenib in Treating Patients with Previously Treated, Metastatic, or Locally Advanced Angiosarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 13S02, NCI-2013-02278, ONC-2013-129, STU00087654, NCT02048722
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients with High-Risk Stage IIB-IV Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00009464, NCI-2013-02414, NCT02050919
Start Over